Louis R DePalo, MD Email Louis DePalo
-
- Positions
- PROFESSOR | Medicine, Pulmonary, Critical Care and Sleep Medicine
- PROFESSOR | Medicine, Infectious Diseases
-
- Specialty
- Pulmonary Medicine
-
- Language
- English
-
- Hospital Affiliations
- Mount Sinai St. Luke's and Mount Sinai West
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
-
- Phone
- Mount Sinai-National Jewish Respiratory Institute 212-241-5656 212-241-5656
-
Mount Sinai-National Jewish Respiratory Institute
10 East 102nd Street
5th Fl
New York, NY 10029
Phone: 212-241-5656212-241-5656
Dr. DePalo is the System Clinical Director of the Respiratory Institute, Mount Sinai Health System and Professor of Pulmonary, Critical Care and Sleep Medicine and Adjunct Professor of Infectious Disease, Icahn School of Medicine. Dr. DePalo is a UNOS certified physician with clinical interest in advanced lung diseases including ILD, hypersensitivity pneumonitis, vasculitis, sarcoidosis, Bronchiectasis, refractory asthma, and lung cancer. He is Co-Director of the Bronchiectasis program and founding member of the Hospital based PERT (pulmonary embolism response team). Dr. DePalo Chairs the system wide Pharmacy and Therapeutics committee and has been active in adoption of new EMR and adjunct technologies to advance patient care and Education. Dr. DePalo, M.D. is a graduate of Georgetown University and New York Medical College. Dr. DePalo has a graduate degree in Human Physiology and extensive research experience in cell and molecular biology. Dr. DePalo's extensive include research interests in the study of human airway smooth muscle cell function, sarcoidosis and advanced lung diseases. Following many years of productive study in the Cardiovascular Institute of The Mount Sinai Hospital, Dr. DePalo directed his research efforts to clinical medicine. In collaboration with Dr. Alvin Teirstein, Dr. DePalo participated in a case controlled epidemiology study of the causes of sarcoidosis (ACCESS Trial) and the study of the genetics of sarcoidosis (SAGA). Dr. DePalo has served as PI for industry sponsored trial on inhaled Liposomal Amikacin which has just had FDA approval and currently investigating new technology for early detection of lung cancer with Bioaffinity sputum assay. Furthermore, in collaboration with Cardiovascular Institute and The Recanati-Miller Transplantation Institute, Dr. DePalo has served as a consultant with the Pulmonary Hypertension, heart Transplant and former Lung Transplant Programs. He serves as consultant for the advanced heart failure team, together with the LVAD and ECMO programs. Dr. DePalo is also a founding member of the Mount Sinai pulmonary embolism response team (PERT). Research in these areas includes the application of new therapeutic and diagnostic modalities to the treatment of patients with these disorders.
Certifications
Critical Care Medicine
Pulmonary Disease
American Board of Internal Medicine
Clinical Focus
- Allergic Bronchopulmonary Aspergillosis (ABPA)
- Arterial Blood Gases
- Aspergillosis
- Asthma
- Bronchiectasis
- Bronchoscopy, Diagnostic
- Chronic Bronchitis
- Chronic Obstructive Pulmonary Disease (COPD)
- Cough
- Cystic Fibrosis
- Emphysema
- Idiopathic Pulmonary Fibrosis
- Lung Cancer
- Non-tuberculous Mycobacterial Infections
- Pleural Mesothelioma
- Pneumococcal Vaccine
- Pneumonia
- Polysomnography
- Pulmonary Embolism
- Pulmonary Function Tests
- Pulmonary Hypertension
- Sarcoidosis
- Scleroderma
- Sleep Apnea
- Thoracentesis
- Tuberculosis
Education
MD, New York Medical College
Residency, Internal Medicine
Mount Sinai Hospital
Residency, Internal Medicine
Mount Sinai Hospital
Fellowship, Pulmonary Crit Care
Hospital of The University Of Penn.
Language
English
I am heavily involved in the implementation of computer technologies to varied programs including medical education, patient care, and information distribution within the medical center and the broader community.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.DePalo did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website.
Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.